ELUT (Elutia) Valuation Rank


ELUT Elutia Inc ELUT
37 GF Score
Price $0.96
GF Value $0.91
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Elutia Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Elutia Valuation Rank Related Terms

ELUT
37GF Score
Elutia Inc ELUT
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Elutia (ELUT) Overvalued in 2026?

Based on GuruFocus' analysis, Elutia stock appears to be overvalued. The current stock price of $0.96 is trading 5.1% above its estimated GF Value™ of $0.91. GuruFocus considers Elutia to be Fairly Valued.

Key valuation signals for ELUT:

  • Valuation Rank:
  • GF Value™: $0.91 vs. price of $0.96 (5.1% above fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the ELUT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elutia Business Description

Address 20 Firstfield Road, Gaithersburg, MD, USA, 20878
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
37GF Score

Get the complete analysis for ELUT

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.91
GF Value